☆ 4.7 Meeting Abstract

Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?

JOURNAL OF CLINICAL ONCOLOGY (2018)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 36, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2018.36.15_suppl.3590

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)

Maria Alessandra Calegari, Lisa Salvatore, Brunella Di Stefano, Michele Basso, Armando Orlandi, Alessandra Boccaccino, Fiorella Lombardo, Alessandra Auriemma, Ina Valeria Zurlo, Maria Bensi, Floriana Camarda, Marta Ribelli, Raffaella Vivolo, Alessandra Cocomazzi, Carmelo Pozzo, Michele Milella, Maurizio Martini, Emilio Bria, Giampaolo Tortora

Summary: The study compared patients with BRAF V600E and BRAF non-V600 metastatic colorectal cancers (mCRCs), finding that patients with BRAF non-V600 mutations had more favorable clinical characteristics and survival rates.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing, Hubing Shi

Summary: The study identified GRB7-PLK1 as a crucial axis mediating RTKs, resulting in tolerance to MEK inhibitors. Therefore, PLK1 is a promising target for enhancing the clinical treatment of CRC patients with KRAS mutations by synergizing with MEK inhibitors.

ONCOGENE (2022)

Add to Collection

Review Oncology

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer

Elisa Grassi, Jody Corbelli, Giorgio Papiani, Maria Aurelia Barbera, Federica Gazzaneo, Stefano Tamberi

Summary: 8-12% of patients with advanced colon rectal cancer present with BRAF alterations, particularly the V600E mutation, which is associated with poor prognosis. New therapeutic options, such as targeted therapy combinations, are emerging for this subgroup of patients. Treatment optimization for this subgroup is an important goal.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer

Gianluca Mauri, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Viviana Gori, Daniela Massihnia, Tiziana Cipani, Francesco Spina, Silvia Ghezzi, Salvatore Siena, Andrea Sartore-Bianchi

Summary: The BRAF(V600E) mutation is detected in 8-10% of patients with metastatic colorectal cancer (mCRC) and has a poor prognostic outlook, with median overall survival below 20 months. Treatment options include immune checkpoint inhibitors (CPIs) for those with concomitant MSI-H status, and a combination of cytotoxic chemotherapy + anti-VEGF or EGFR and BRAF inhibitors for first and second line treatment, respectively. However, acquired resistance limits the potential benefits and survival remains poor. Ongoing clinical trials are exploring various strategies to improve treatment outcomes for this subset of patients.

CANCERS (2021)

Add to Collection

Review Oncology

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer

Erika Martinelli, Dirk Arnold, Andres Cervantes, Sebastian Stintzing, Eric Van Cutsem, Josep Tabernero, Julien Taieb, Harpreet Wasan, Fortunato Ciardiello

Summary: This article reviews the current knowledge and consensus management on the clinical management of BRAFV600E-mutant metastatic colorectal cancer (mCRC). The treatment landscape for this specific type of mCRC has changed greatly due to the emergence of molecular targeted therapies and immune checkpoint inhibitors. Tumor tissue analysis for DNA mismatch repair/microsatellite status and KRAS, NRAS, and BRAF mutational status is mandatory for appropriate clinical management and treatment decisions.

CANCER TREATMENT REVIEWS (2023)

Add to Collection

Article Oncology

STARBOARD: encorafenib plus binimetinib plus pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma

Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy Panella, Meredith McKean, Edgardo S. Santos, Kimberli Brill, Anna Polli, Alessandra di Pietro, Paolo A. Ascierto

Summary: Despite significant progress in the treatment of BRAF-mutant melanoma, there are still limitations in terms of efficacy. This study aims to evaluate the efficacy and safety of combined targeted therapy and immunotherapy to further improve patient outcomes.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens

Lauren Y. Cheng, Lauren E. Haydu, Ping Song, Jianyi Nie, Michael T. Tetzlaff, Lawrence N. Kwong, Jeffrey E. Gershenwald, Michael A. Davies, David Yu Zhang

Summary: The study demonstrates that the NuProbe VarTrace BRAF sequencing technology can detect BRAF V600 mutations down to 0.20% VAF from FFPE lymph node tissue samples, with high concordance among various methods for samples with VAF>=1% BRAF mutations, but with possible false negatives in IHC. The BDA Sanger method is effective for rapid detection and quantitation of multiple low VAF BRAF mutations.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients

E. Berrino, A. Balsamo, A. Pisacane, S. Gallo, P. Becco, U. Miglio, D. Caravelli, S. Poletto, L. Paruzzo, C. Debernardi, C. Piccinelli, A. Zaccagna, P. Rescigno, M. Aglietta, A. Sapino, F. Carnevale-Schianca, T. Venesio

Summary: This study found a highly heterogeneous BRAF VAF in melanoma patients, which was correlated with age, lymphocytic infiltration, melanoma thickness, and metastatic sites. A BRAF VAF >25% was associated with favorable outcomes in patients treated with anti-BRAF/anti-MEK therapy, acting as an independent prognostic factor in multivariate analysis.

ESMO OPEN (2021)

Add to Collection

Article Clinical Neurology

The clinico-pathological characterisation of focal cortical dysplasia type IIb genetically defined by MTOR mosaicism

Yajie Wang, Tao Yu, Ingmar Bluemcke, Yanning Cai, Ke Sun, Runshi Gao, Yujiao Wang, Yongjuan Fu, Wei Wang, Yuping Wang, Guojun Zhang, Yueshan Piao

Summary: This study used next generation sequencing to reveal frequent MTOR mutations in patients with FCD IIb and identified genotype-phenotype associations including non-temporal lobe lesion, larger lesion volume, and increased balloon cells and dysmorphic neurons.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2023)

Add to Collection

Article Oncology

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma

Karisa C. Schreck, Andrew Morin, Guisheng Zhao, Amy N. Allen, Patrick Flannery, Michael Glantz, Adam L. Green, Chris Jones, Kenneth L. Jones, Lindsay B. Kilburn, Kellie J. Nazemi, David Samuel, Bridget Sanford, David A. Solomon, Jiawan Wang, Christine A. Pratilas, Theodore Nicolaides, Jean M. Mulcahy Levy

Summary: This study identified various resistance mechanisms to BRAFi in gliomas, suggesting the need for combination therapies. Different resistance mechanisms require specific strategies to overcome, such as restoring wild-type PTEN or combination therapy with MEKi or EGFR inhibitors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

A. Grothey, M. Fakih, J. Tabernero

Summary: Colorectal cancer remains a leading cause of cancer-related deaths globally, with the mutation in the BRAF gene, particularly the V600E substitution, affecting 10% of metastatic CRC patients and indicating a poor prognosis. Recent advancements in combination therapies targeting the MAPK pathway have shown promising results in treating BRAF V600E-mutated mCRC patients, offering new hope in the management of this subtype of cancer.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania

Vlad-Adrian Afrasanie, Mihai-Vasile Marinca, Bogdan Gafton, Teodora Alexa-Stratulat, Alexandra Rusu, Eliza-Maria Froicu, Daniel Sur, Cristian Virgil Lungulescu, Larisa Popovici, Andrei-Vlad Lefter, Irina Afrasanie, Anca-Viorica Ivanov, Lucian Miron, Cristina Rusu

Summary: In this study, the frequency, distribution, coexistence, and clinicopathological and molecular correlations of RAS, BRAF, PIK3CA, and TP53 mutations were investigated in 104 patients with metastatic colorectal cancer from Northeastern Romania. TP53 was the most frequently mutated gene (73.1%), followed by KRAS (45.2%) and PIK3CA (6.7%). The study provides novel insights into genetic variations specific to the population from Northeastern Romania and enables the development of genetic profiles in a developing country with limited access to specialized genetic tests.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer

Ting Xu, Jian Li, Zhenghang Wang, Xiaotian Zhang, Jun Zhou, Zhihao Lu, Lin Shen, Xicheng Wang

Summary: This study retrospectively analyzed the clinical data of patients between June 2010 and December 2021 and found an association between BRAF V600E mutation and poor and heterogeneous prognosis. First-line intensive chemotherapy had limited impact on progression-free survival and overall survival in patients with BRAF V600E mutant metastatic colorectal cancer.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment

Sheehyun Kim, Yoojoo Lim, Jun-Kyu Kang, Hwang-Phill Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim

Summary: This study analyzed serial blood samples from metastatic colorectal cancer patients and sequenced ctDNA to evaluate its clinical utility. The results showed that ctDNA clearance after chemotherapy was associated with longer progression-free survival, independent of radiological response. Longitudinal ctDNA monitoring detected ctDNA progression earlier than radiological progressive disease in a significant percentage of patients.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice

Raffaella D'Onofrio, Francesco Caputo, Francesco Prampolini, Andrea Spallanzani, Fabio Gelsomino, Stefania Bettelli, Samantha Manfredini, Luca Reggiani Bonetti, Pietro Carotenuto, Alessandro Bocconi, Massimo Dominici, Gabriele Luppi, Massimiliano Salati

Summary: In this study, extended ctDNA-based RAS genotyping was applied to select eligible colorectal cancer patients for anti-EGFR treatment. The results showed that this approach had a higher objective response rate and longer survival compared to traditional clinical criteria, highlighting the importance of blood-based genetic testing in precision medicine.

TUMORI JOURNAL (2023)

Add to Collection

Article Surgery

Demystifying BRAF Mutation Status in Colorectal Liver Metastases A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Georgios A. Margonis, Thomas Boerner, Jean-Baptiste Bachet, Stefan Buettner, Roberto Moretto, Nikolaos Andreatos, Andrea Sartore-Bianchi, Jane Wang, Carsten Kamphues, Johan Gagniere, Sara Lonardi, Inger M. Loes, Doris Wagner, Andrea Spallanzani, Kazunari Sasaki, Richard Burkhart, Filippo Pietrantonio, Emmanouil Pikoulis, Timothy M. Pawlik, Stephanie Truant, Armando Orlandi, Anastasia Pikouli, Nicoletta Pella, Katharina Beyer, George Poultsides, Hendrik Seeliger, Federico N. Aucejo, Peter Kornprat, Klaus Kaczirek, Per E. Lonning, Martin E. Kreis, Christopher L. Wolfgang, Matthew J. Weiss, Chiara Cremolini, Stephane Benoist, Michael D'Angelica

Summary: This study investigated the clinical implications of BRAF-mutated colorectal liver metastases. The results showed that BRAF V600E mutation was associated with shorter overall survival but not recurrence-free survival. Patients with MSS tumors had shorter recurrence-free survival compared with those with MSI-high tumors. Resection of converted disease resulted in encouraging survival. Second hepatectomy improved outcomes for patients with recurrence.

ANNALS OF SURGERY (2023)

Add to Collection

Editorial Material Nutrition & Dietetics

The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition

Amanda Casirati, Valentina Da Prat, Emanuele Cereda, Francesco Serra, Lorenzo Perrone, Salvatore Corallo, Francesco De Lorenzo, Paolo Pedrazzoli, Riccardo Caccialanza

NUTRIENTS (2023)

Add to Collection

Review Medicine, General & Internal

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis

Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Summary: This systematic review and meta-analysis examined the use of CDK4/6 inhibitors in hormone-receptor positive/HER2-negative metastatic breast cancer. The study found that CDK4/6 inhibitors had a significant benefit in terms of progression-free survival compared to placebo. In terms of adverse events, different CDK4/6 inhibitors had varying advantages and disadvantages. The study confirmed the reliability of LHH as a tool for balancing the risks and benefits of experimental drugs.

ECLINICALMEDICINE (2023)

Add to Collection

Article Oncology

COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study

Nicola Fazio, Lorenzo Gervaso, Thorvardur R. Halfdanarson, Mohamad Sonbol, Rachel A. Eiring, Sara Pusceddu, Natalie Prinzi, Benedetta Lombardi Stocchetti, Simona Grozinsky-Glasberg, David J. Gross, Thomas Walter, Patrick Robelin, Catherine Lombard-Bohas, Samuele Frassoni, Vincenzo Bagnardi, Lorenzo Antonuzzo, Clotilde Sparano, Sara Massironi, Fabio Gelsomino, Alberto Bongiovanni, Nicoletta Ranallo, Salvatore Tafuto, Maura Rossi, Mauro Cives, Ibrahim Rasul Kakil, Hytam Hamid, Alessandra Chirco, Michela Squadroni, Anna La Salvia, Jorge Hernando, Johannes Hofland, Anna Koumarianou, Sabrina Boselli, Darina Tamayo, Cristina Mazzon, Manila Rubino, Francesca Spada

Summary: This study investigated patients with neuroendocrine neoplasms (NENs) and confirmed SARS-CoV-2 positivity at the molecular level through a retrospective/prospective worldwide study. The findings indicate a decreasing trend in the incidence of COVID-19 over the years, with older age, non-gastroenteropancreatic primary sites, and diabetes mellitus associated with increased severity and mortality of COVID-19.

ENDOCRINE-RELATED CANCER (2023)

Add to Collection

Article Oncology

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Francesco Cortiula, Dirk De Ruysscher, Michelle Steens, Robin Wijsman, Anthonie van der Wekken, Martina Alberti, Lizza E. L. Hendriks

Summary: Adjuvant durvalumab is the standard treatment for stage III unresectable non-small cell lung cancer (NSCLC) patients without progression after chemo-radiation. Patients with EGFR mutations and ALK rearrangements do not benefit from durvalumab. This retrospective study showed that patients with uncommon driver genomic alterations (dGA), including KRAS mutations, had a meaningful survival benefit from adjuvant durvalumab.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis

Maria Sofia Ciliento, Veronica Venturelli, Natale Schettini, Riccardo Bertola, Carlo Garaffoni, Giovanni Lanza, Roberta Gafa, Alessandro Borghi, Monica Corazza, Alen Zabotti, Sonia Missiroli, Caterina Boncompagni, Simone Patergnani, Mariasole Perrone, Carlotta Giorgi, Paolo Pinton, Marcello Govoni, Carlo Alberto Scire, Alessandra Bortoluzzi, Ettore Silvagni

Summary: The aim of this systematic literature review was to investigate the effects of b/tsDMARDs on the synovial membrane of PsA patients and identify biomarkers of response to therapy. A meta-analysis of 22 studies showed a significant reduction in CD3+ lymphocytes and CD68+ macrophages in synovial biopsies from patients treated with bDMARDs for 4-12 weeks. Reduction in CD3+ was correlated with clinical response. The most consistent finding in the literature was the reduction in CD3+/CD68+ sublining cells during the first 3 months of treatment with TNF inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis

Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell'Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, Giovanni Dima, Giovanni Trovato, Silvia Riondino, Mario Roselli, Ferdinandos Skoulidis, Hendrik-Tobias Arkenau, Chiara Cremolini

Summary: This retrospective study compared the effectiveness of irinotecan and oxaliplatin in the first-line treatment of KRASG12C-mutated colorectal cancer. The results demonstrated that irinotecan provided better survival outcomes, indicating that it should be preferred over oxaliplatin. These findings are important for investigating chemotherapy plus targeted agent combinations.

CANCERS (2023)

Add to Collection

Article Oncology

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting

Antonio Franco, Alba Di Leone, Alessandra Fabi, Paolo Belli, Luisa Carbognin, Elisabetta Gambaro, Fabio Marazzi, Elena Jane Mason, Antonino Mule, Armando Orlandi, Antonella Palazzo, Ida Paris, Alessandro Rossi, Lorenzo Scardina, Daniela Andreina Terribile, Giordana Tiberi, Diana Giannarelli, Giovanni Scambia, Riccardo Masetti, Gianluca Franceschini

Summary: Screening programs have led to a decrease in the diagnosis of locally advanced breast cancer, but the optimal surgical treatment strategy is still under debate. This study compared conservative breast surgery (CBS) with radical breast surgery (RBS) in cT4 breast cancer patients who underwent neoadjuvant chemotherapy (NA) and surgery. The results suggest that CBS may be a safe alternative to RBS in patients with major or complete response to NA, while RBS remains the best choice for patients with poor response to NA.

CANCERS (2023)

Add to Collection

Editorial Material Oncology

A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

F. Cortiula, J. Naidoo

LUNG CANCER (2023)

Add to Collection

Article Oncology

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

Pietro Sollena, Nikolaou Vasiliki, Elias J. Kotteas, Alexander J. Stratigos, Davide Fattore, Armando Orlandi, Maria Mannino, Marcello Di Pumpo, Monika Fida, Michela Starace, Zoe Apalla, Maria Concetta Romano, Julia Riganti, Sonia Segura, Azael Freites Martinez, Gabriella Fabbrocini, Vincent Sibaud, Ketty Peris

Summary: Treatment with CDK4/6 inhibitor in combination with endocrine therapies can improve progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. However, limited data exists on its cutaneous adverse events. This retrospective study investigated the prevalence, types, and management of cutaneous adverse events during CDK4/6 inhibitor treatment.

CANCERS (2023)

Add to Collection

Article Health Care Sciences & Services

An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy

Antonio Franco, Alba Di Leone, Marco Conti, Alessandra Fabi, Luisa Carbognin, Andreina Daniela Terribile, Paolo Belli, Armando Orlandi, Martin Alejandro Sanchez, Francesca Moschella, Elena Jane Mason, Giovanni Cimino, Alessandra De Filippis, Fabio Marazzi, Ida Paris, Giuseppe Visconti, Liliana Barone Adesi, Lorenzo Scardina, Sabatino D'Archi, Marzia Salgarello, Diana Giannarelli, Riccardo Masetti, Gianluca Franceschini, Kenneth P. H. Pritzker

Summary: This study developed a post-Neoadjuvant Score System (pNESSy) to choose the appropriate surgery and improve oncological and aesthetic outcomes. The system uses clinical and radiological features to predict the optimal surgery method post-neoadjuvant chemotherapy.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

Article Cell Biology

Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca2+ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells

Pawan Faris, Agnese Rumolo, Giorgia Pellavio, Matteo Tanzi, Mauro Vismara, Roberto Berra-Romani, Andrea Gerbino, Salvatore Corallo, Paolo Pedrazzoli, Umberto Laforenza, Daniela Montagna, Francesco Moccia

Summary: Colorectal carcinoma (CRC) is a common cancer and a leading cause of cancer-related death. Activation of TRPA1 channel by oxidative stress may lead to mitochondrial ion imbalance and apoptosis in metastatic CRC cells. Targeting TRPA1 could enhance the sensitivity of CRC to oxidative stress and potentially eradicate metastatic CRC.

CELL DEATH DISCOVERY (2023)

Add to Collection

Article Oncology

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis

Ingrid Garajova, Fabio Gelsomino, Massimiliano Salati, Francesco Leonardi, Stefania De Lorenzo, Alessandro Granito, Francesco Tovoli

Summary: This study aimed to investigate the prognostic role of bone metastases in patients with intrahepatic cholangiocarcinoma. Among 186 patients, around 11% developed bone metastases, which were associated with shorter median overall survival compared to patients with liver involvement only. Poor performance status and absence of second-line treatment were also associated with worse outcomes.

CURRENT ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.